en.Wedoany.com Reported - Researchers at the University of Cambridge have developed a "universal vaccine" using artificial intelligence technology, aiming to intercept risks before the next pandemic emerges. This marks the first human clinical trial where the active ingredient is entirely computer-designed, with no significant side effects observed.

The researchers administered the vaccine to 39 healthy volunteers aged 18 to 50 at two medical institutions in Southampton and Cambridge, UK. The vaccine primarily targets Sarbeco coronaviruses, with its core active ingredient being a novel antigen.

The trial showed that volunteers developed protective immune responses against SARS-CoV-2, SARS, and related bat viruses that could potentially cause future pandemics. Based on this development approach, the vaccine may even offer protection against emerging diseases that have not yet appeared.

Traditional vaccines are typically developed only after an outbreak, often struggling to keep pace with rapidly mutating viruses. In contrast, this new antigen is expected to provide an integrated protection solution against diseases that can spread among humans, such as influenza and Ebola.

Professor Jonathan Heeney from the Laboratory of Viral Zoonotics at the University of Cambridge's Department of Veterinary Medicine stated that vaccine development has shifted from reactive to proactive, ensuring continued protection even if the virus mutates into new strains. He noted that traditional vaccines have limited protection scope, and this new technology overcomes that limitation, helping to break the cycle of constantly tracking circulating virus variants and updating vaccines.

During the development process, the team fed all globally recorded genetic sequence data of Sarbeco coronaviruses into the AI model, using machine learning to design an antigen that embodies the common characteristics of the entire virus group.

Given the small sample size of this trial, the next phase will involve larger and more diverse participants to further evaluate the vaccine's efficacy.

This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com